The global contest recognized Infosys for its use of next generation technologies for innovation in the area of engineering design. The winning team at Infosys developed an active three-dimensional model that simulates the working of the human heart. The model provides medical professionals and scientists with a near real-life scenario to improve understanding of the complexities of human heart disorders.
• Dattatraya Parle, Principal Consultant and Anirudha Ambulgekar, Engineering Analyst, at Infosys Engineering Services, in collaboration with medical experts, designed the award-winning model of the human heart;
• The model simulates the heart’s functioning, in particular the deformation of heart tissues due to certain stress conditions. This will help medical professionals diagnose heart disorders faster and with a higher level of precision;
• The model will also help medical device manufacturers test and validate implants to detect and correct any anomalies quickly. This is expected to lead to better-designed medical devices, faster regulatory and compliance approval and improved time-to-market for those devices;
• The advanced engineering concepts developed by the team can be directly leveraged for other areas of biomedical research and development, such as modeling and validation of prosthetics;
• Other winners of this year’s awards include NASA, Jaguar and Land Rover. The winners were chosen for their ability to demonstrate leading-edge product design, and showcase business benefits of the product and the impact of the product on human society or industry.
With 8500+ engineers and client partnerships with Global 500 companies in more than 30 countries, Infosys Engineering Services provides a wide range of services for the complete engineering product lifecycle, ranging from product ideation to realization and sustenance.
Ashok Vemuri, Head of Americas, Global Head of Manufacturing and Engineering Services, Infosys
“Biomedical device manufacturers are looking for solutions that can help them not only design innovative devices but also accelerate testing and validation of products to enable faster time-to-market of their products. Infosys continues to push the boundaries of biomedical engineering to help our clients deliver better-designed devices to patients faster. This award is yet another testimony to our focus on accelerating innovation for our clients and our growing leadership in the engineering services space.”
Infosys (infosys.com) is a global leader in business consulting and technology solutions. As a proven partner focused on building tomorrow’s enterprise, Infosys enables clients in more than 30 countries to outperform the competition and stay ahead of the innovation curve. Ranked in the top tier of Forbes’ 100 most innovative companies, Infosys with $7B in annual revenues and 150,000+ employees provides enterprises with strategic insights on what lies ahead. We help enterprises transform and thrive in a changing world through strategic consulting, operational leadership and the co-creation of breakthrough solutions, including those in mobility, sustainability, big data and cloud computing.
Certain statements in this release concerning our future growth prospects are forward-looking statements, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, fluctuations in foreign exchange rates, our ability to manage growth, intense competition in IT services including those factors which may affect our cost advantage, wage increases in India, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, restrictions on immigration, industry segment concentration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks or system failures, our ability to successfully complete and integrate potential acquisitions, liability for damages on our service contracts, the success of the companies in which Infosys has made strategic investments, withdrawal or expiration of governmental fiscal incentives, political instability and regional conflicts, legal restrictions on raising capital or acquiring companies outside India, and unauthorized use of our intellectual property and general economic conditions affecting our industry. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings including our Annual Report on Form 20-F for the fiscal year ended March 31, 2013 and on Form 6-K for the quarters ended June 30, 2012, September 30, 2012 and December 31, 2012.These filings are available at sec.gov. Infosys may, from time to time, make additional written and oral forward-looking statements, including statements contained in the company's filings with the Securities and Exchange Commission and our reports to shareholders. The company does not undertake to update any forward-looking statements that may be made from time to time by or on behalf of the company, unless required by law.